NRx Pharmaceuticals Management

Management criteria checks 3/4

NRx Pharmaceuticals' CEO is Steve Willard, appointed in Jul 2022, has a tenure of 1.83 years. total yearly compensation is $500.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.01% of the company’s shares, worth €274.60K. The average tenure of the management team and the board of directors is 2 years and 1.8 years respectively.

Key information

Steve Willard

Chief executive officer

US$500.0k

Total compensation

CEO salary percentage	100.0%
CEO tenure	1.8yrs
CEO ownership	1.0%
Management average tenure	2yrs
Board average tenure	1.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Willard's remuneration changed compared to NRx Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$500k	US$500k	-US$30m
Sep 30 2023	n/a	n/a	-US$36m
Jun 30 2023	n/a	n/a	-US$39m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$1m	US$234k	-US$40m

Compensation vs Market: Steve's total compensation ($USD500.00K) is about average for companies of similar size in the German market ($USD394.06K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Willard (62 yo)

1.8yrs

Tenure

US$500,000

Compensation

Mr. Stephen H. Willard, also known as Steve, Esq. serves as Acting Corporate Secretary at NRx Pharmaceuticals, Inc. He serves as Chief Executive Officer and Director at NRx Pharmaceuticals, Inc. since July...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jonathan Javitt	Co-Founder	less than a year	US$630.20k	14.17% $ 3.9m
Stephen Willard	Acting Corporate Secretary	1.8yrs	US$500.00k	1.01% $ 274.6k
Richard Narido	CFO & Treasurer	less than a year	US$298.02k	no data
Riccardo Panicucci	Chief Manufacturing & Technology Officer	3.3yrs	US$240.00k	no data
Suzanne Messere	Investor Relations	no data	no data	no data
Philip Lavin	Chief Methodologist	no data	no data	no data
Dennis McBride	Chief Strategy Officer & Senior Scientist	6.6yrs	no data	no data
Matthew Duffy	Chief Business Officer	1.2yrs	no data	no data

2.0yrs

Average Tenure

62yo

Average Age

Experienced Management: B1Q's management team is considered experienced (2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jonathan Javitt	Co-Founder	less than a year	US$630.20k	14.17% $ 3.9m
Stephen Willard	Acting Corporate Secretary	1.8yrs	US$500.00k	1.01% $ 274.6k
Chaim Hurvitz	Independent Director	3yrs	US$52.50k	2.13% $ 579.2k
Patrick Flynn	Independent Director	3yrs	US$67.50k	0.57% $ 154.4k
Janet Rehnquist	Independent Director	less than a year	no data	no data

1.8yrs

Average Tenure

65yo

Average Age

Experienced Board: B1Q's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

NRx Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Less than half of directors are independent

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

NRx Pharmaceuticals, Inc. Announces the Appointment of Stephen Willard as its Chief Executive Officer

High number of new and inexperienced directors

Recent updates

NRx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results

NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.0031 million.

NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics

NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

NRx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Less than half of directors are independent

NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

Panel Grants NRx Pharmaceuticals Request for an Exception to Nasdaq Listing Rules Until April 16, 2024, to Demonstrate Compliance with the Rule

NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

NRx Pharmaceuticals Demonstrates Compliance with Nasdaq MVLS Standard

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

NRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

NRx Pharmaceuticals Receives Formal Notice from the Listing Qualifications Staff of Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

NRx Pharmaceuticals, Inc. Announces New Data That Demonstrates Potent in Vitro Activity of NRx-101

NRx Pharmaceuticals Announces Submission of an Investigational New Drug Application for NRX -101 in the Treatment of Chronic Pain

NRx Pharmaceuticals, Inc. announced that it expects to receive $1.2 million in funding

NRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

NRx Pharmaceuticals Receives Written Notification from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities

NRx Pharmaceuticals, Inc. Reports Minutes of U.S. Food and Drug Administration Meeting on Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality

NRx Pharmaceuticals, Inc. Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

NRx Pharmaceuticals, Inc. Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

NRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

NRx Pharmaceuticals, Inc. Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding

NRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022

NRx Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

NRx Pharmaceuticals, Inc. Announces the Appointment of Stephen Willard as its Chief Executive Officer

Nrx Pharmaceuticals, Inc. Announces FDA Declines Emergency Use Authorization for Zyesami® (Aviptadil) for Subgroup of Patients with Critical Covid-19 At Immediate Risk of Death from Respiratory Failure Despite Treatment with Approved Therapy, Including Remdesivir

High number of new and inexperienced directors

NRx Pharmaceuticals, Inc. Announces Class Action Suit Against the Company Dismissed

Nrx Pharmaceuticals, Inc. Announces Director Resignation

NRx Pharmaceuticals, Inc., Annual General Meeting, Jul 18, 2022

NRx Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Denied for aviptadil

NRx Pharmaceuticals, Inc. Provides Update on Breakthrough Therapy Designation Request for ZYESAMI® (Aviptadil)

NRx Pharmaceuticals Appoints Seth Van Voorhees as Chief Financial Officer, Effective June 13, 2022

Co-Founder recently bought €54k worth of stock

NRx Pharmaceuticals, Inc. Announces Executive Changes

NRx Pharmaceuticals, Inc. Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19

High number of new and inexperienced directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age